OpenAI researcher Miles Wang is reportedly preparing to launch a new artificial intelligence startup focused on accelerating drug discovery, marking another high-profile move in the growing intersection of AI and life sciences. According to multiple reports, Wang is leaving OpenAI to build a company that will develop AI models capable of improving pharmaceutical research and identifying promising treatment opportunities.
The proposed venture has already attracted significant investor attention. Reports indicate the company is in discussions to raise approximately $200 million, with a potential valuation of around $2 billion, although negotiations are ongoing and the final terms have not been confirmed.
New Venture Aims to Advance AI-Powered Drug Research
The startup is expected to focus on applying advanced AI models to pharmaceutical development, helping researchers analyse biological data more efficiently and identify potential medicines faster than conventional research methods.
Instead of focusing solely on brand-new compounds, the company is reportedly examining how artificial intelligence can reveal fresh clinical opportunities within medicines that are already known to researchers.
Investor Interest in AI Healthcare Continues to Grow
Investment activity surrounding AI-driven biotechnology companies has accelerated in recent months as venture capital firms continue backing businesses developing next-generation healthcare technologies.
Growing confidence in artificial intelligence for scientific research has encouraged investors to support startups building models capable of improving drug development, molecular analysis, and medical research.
If completed, the reported funding round would place Wang’s new company among the highest-valued AI healthcare startups launched this year.
Miles Wang Built His Reputation at OpenAI
Miles Wang joined OpenAI in 2024 after studying computer science at Harvard, where he left before completing his degree to pursue research opportunities.
During his time at OpenAI, he contributed to projects examining how artificial intelligence can accelerate scientific research, particularly in biology and related fields. His work explored ways AI systems could assist researchers in analysing complex scientific problems more efficiently.
Several reports also suggest that additional OpenAI researchers may join the new venture as the company expands.
AI Is Transforming Pharmaceutical Innovation
Artificial intelligence is becoming an increasingly valuable tool across the pharmaceutical industry, supporting tasks such as molecular prediction, clinical research, and treatment discovery.
Rather than replacing scientists, AI platforms are designed to process large volumes of biological information, helping research teams identify promising candidates more quickly and improve decision-making throughout the drug development process.
This combination of human expertise and machine learning continues attracting substantial investment from both the technology and healthcare sectors.
Competition in AI Drug Discovery Is Intensifying
The healthcare AI market has become increasingly competitive as new startups emerge alongside established technology companies investing heavily in medical research.
Businesses developing AI-powered drug discovery platforms are competing to improve research efficiency, lower development costs, and shorten the time required to bring new treatments closer to clinical use.
With investor confidence remaining strong, the sector is expected to remain one of the fastest-growing areas within artificial intelligence.
Frequently Asked Questions
Who is Miles Wang?
Miles Wang is an OpenAI researcher known for contributing to AI research focused on accelerating scientific and biological discovery.
What will the new startup develop?
The company is expected to build artificial intelligence models designed to support drug discovery and pharmaceutical research.
Has the funding round been confirmed?
No. Reports indicate discussions are ongoing, and neither the funding amount nor the final valuation has been officially confirmed.
